New Target for Treatment of Parkinson’s Disease

Sharon Ronit, HUJI, School of Medicine - IMRIC, Biochemistry and Molecular Biology


Parkinson’s disease, PD, Central Nervous System, CNS

Current development stage

TRL3 - Hypothesis testing and intial POC demonstrated in limited number of in-vitro models; 

Our Innovation

  • Parkinson disease (PD) is a long-term, progressive neurodegenerative disorder of the central nervous system, which results in motor and non-motor dysfunction. The disease is primarily related to loss of dopaminergic function. The market of Parkinson’s disease treatments is driven by the growth in aging population and the associated increase in the prevalence of PD, however , there is currently no cure for Parkinson's disease, with treatment mostly associated with Dopamine replacement therapy, directed at improving symptoms.
  • The Researcher identified a possibly new target , with proposed mechanism of action associated with α-Syn toxicity in PD.  Initial pre-clinical results suggest a novel therapeutic approach , using specific inhibitors to stop progression of Parkinson’s disease.



Contact for more information:

Mel Larrosa
VP Business Development Healthcare
Contact ME: